Movapo: Apomorphine belongs to the class of medications called anti-Parkinson's agents. It is used to treat the early return of stiffness and movement problems that occur when the effects of other medications for Parkinson's disease wear off early.

MOVAPO PEN is used in the treatment of Parkinson’s disease to reduce the number and severity of bouts of freezing and stiffness (or “off” periods). For more information, see Section 1. Why am I using MOVAPO PEN? in the full CMI. 2. What should I know before I use MOVAPO PEN?

2020年5月6日 · Movapo Pen, apomorphine hydrochloride hemihydrate 30 mg/3 mL is a disposable multiple dose pen injector system incorporating a clear glass (type I) cartridge containing a clear solution for injection.

Australian Register of Therapeutic Goods (ARTG) information for MOVAPO PEN apomorphine hydrochloride hemihydrate 30 mg/3 mL Solution for Injection, Cartridge.

MOVAPO PEN is a clear, colourless and practically particle free sterile solution for injection with a pH of 3.0 to 4.0. MOVAPO PEN is indicated to reduce the number and severity of ‘off’ phases in patients with Parkinson’s disease severely disabled by motor fluctuations refractory to conventional therapy.

Apomorphine is used in the treatment of Parkinson’s disease to reduce the number and severity of bouts of freezing and stiffness (or “off” periods). This medicine works by acting on dopamine receptors. These receptors help control movement by the body. Ask your doctor if you have any questions about why this medicine has been prescribed for you.

2018年8月3日 · apo-go ® /movapo [®/] 注射液是治疗帕金森的一种常规疗法。帕金森疾病的特征是脑中含多巴胺的神经元出现进行性退化，进而导致患者丧失运动控制能力。

MOVAPO (Apomorphine hydrochloride 10 mg/mL) is indicated for: • The acute, intermittent treatment of hypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson’s disease.

Movapo® is indicated for the acute, intermitent treatment of hypomobility, “OFF episodes (“end-of-dose wearing off and unpredictable “ON/OFF” episodes) in patients with advanced Parkinson’s disease. It is an apomorphine hydrochloride injection (10 mg/mL), supplied as pre-filled pens.

MOVAPO PEN is indicated to reduce the number and severity of 'off' phases in patients with Parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. Initiation of therapy with apomorphine should be undertaken in a specialist unit in a …